MGMT and glioblastoma: The recently published SNO/EANO consensus article (16) summarizes the role of TTFields in newly diagnosed GBM patients aged 18 to 70 years with good functional status as compared to poor performing newly diagnosed GBM patients aged 65 to 70 years, and evaluated both MGMT-methylated and unmethylated patients in both groups (Figure 1).